Prot #I35316/NU RP17I03: A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Project: Research project

Project Details

StatusFinished
Effective start/end date8/20/18 → 8/20/24

Funding

  • Roswell Park Cancer Institute ((OE) Prot #I35316/NU RP17I03 // (OE) Prot #I35316/NU RP17I03)
  • Merck Sharp & Dohme Corporation ((OE) Prot #I35316/NU RP17I03 // (OE) Prot #I35316/NU RP17I03)